A pilot study in Serbia by European Clostridium difficile Infection Surveillance Network
Acta Microbiologica et Immunologica Hungarica · 09.12.2019 · 67 (1) · 42-48
DOI: 10.1556/030.66.2019.023 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, erschienen am 09.12.2019. Verfasst von Milica Jovanović und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology,Clinical Center of Serbia, Belgrade,Serbia. Hauptthemen laut MEDLINE: Epidemiological Monitoring. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Clostridium (Clostridioides) difficile infections (CDIs) are among the most frequent healthcare-associated infections in Serbia. In 2013, Serbia participated in the European Clostridium difficile Infection Surveillance Network (ECDIS-Net) who launched a pilot study to enhance laboratory capacity and standardize surveillance for CDI. Two clinics of Clinical Center of Serbia [Clinic for Infectious and Tropical Diseases (CITD) and Clinic of Orthopedic Surgery and Traumatology (COT)] from Belgrade and one general hospital from another metropolitan area of Serbia, Užice, participated. During a period of 3 months in 2013, all patients with diagnosed CDI were included. The CDI incidence rates in CITD, COT, and General Hospital Užice were 19.0, 12.2, and 3.9 per 10,000 patient-days, respectively. In total, 49 patients were enrolled in the study with average age of 72 years. A complicated course of CDI was found in 14.3% of all patients. Six (12.2%) of 49 patients died, but not attributable to CDI. Of 39 C. difficile isolates, available for ribotyping, 78.9% belonged to ribotype 027; other PCR ribotypes were 001, 015, 002, 005, 010, 014, and 276. Antimicrobial susceptibility testing revealed low levels of MIC 50 and MIC 90 for metronidazole (0.5 μg/ml both) and vancomycin (0.25 and 0.5 μg/ml), while 28 strains of ribotype 027 were resistant to moxifloxacin with MIC ≥4 μg/ml. National surveillance is important to obtain more insight in the epidemiology of CDI and to compare the results with other European countries. This study by ECDIS-Net gives bases for a national surveillance of CDI in Serbia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology,Clinical Center of Serbia, Belgrade,Serbia.
- National Reference Laboratory forClostridium difficile, Department of Medical Microbiology,Leiden University Medical Center, Leiden,Netherlands.
- Center for Disease Prevention and Control,National Institute for Public Health "Dr Milan Jovacnović Batut", Belgrade,Serbia.
- Department of Microbiology,General Hospital Užice, Užice,Serbia.
- Department of Infectious Diseases,General Hospital Užice, Užice,Serbia.
- Clinic of Orthopedic Surgery and Traumatology,Clinical Center of Serbia, Belgrade,Serbia.
Zitieren
APA
Jovanović, M., van Dorp, S. M., Drakulović, M., Papić, D., Pavić, S., Jovanović, S., Lešić, A., Korać, M., Milošević, I., & Kuijper, E. J. (2019). A pilot study in Serbia by European Clostridium difficile Infection Surveillance Network. Acta Microbiologica et Immunologica Hungarica, 67(1), 42-48. https://doi.org/10.1556/030.66.2019.023
Vancouver
Jovanović M, van Dorp SM, Drakulović M, Papić D, Pavić S, Jovanović S, et al. A pilot study in Serbia by European Clostridium difficile Infection Surveillance Network. Acta Microbiologica et Immunologica Hungarica. 2019;67(1):42-48. doi:10.1556/030.66.2019.023
BibTeX
@article{Jovanovi2019,
author = {Jovanović, Milica and van Dorp, Sofie M and Drakulović, Mitra and Papić, Dubravka and Pavić, Sladjana and Jovanović, Snežana and Lešić, Aleksandar and Korać, Miloš and Milošević, Ivana and Kuijper, Ed J},
title = {A pilot study in Serbia by European Clostridium difficile Infection Surveillance Network},
journal = {Acta Microbiologica et Immunologica Hungarica},
year = {2019},
volume = {67},
number = {1},
pages = {42--48},
doi = {10.1556/030.66.2019.023}
}
EUVIMED